Gsk (GLAXF) Tax Provisions (2009 - 2026)

Gsk's Tax Provisions history runs 18 years deep, the most recent figure standing at -$411.2 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 2.84% year-over-year to -$411.2 million; the TTM figure through Mar 2026 stood at -$2.6 billion (down 96.76% YoY), while the FY2025 annual figure was $1.5 billion, up 118.06% from the prior year.
• Tax Provisions was -$411.2 million for Q1 2026 at Gsk, up from -$1.5 billion in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $1.3 million in Q3 2024 to a low of -$1.5 billion in Q4 2025.
• Historically, Tax Provisions has averaged -$467.5 million across 5 years, with a median of -$347.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions surged 100.4% in 2024, then sank 32502.13% in 2025.
• A 5-year view of Tax Provisions shows it stood at -$829.3 million in 2022, then slipped by 13.15% to -$938.3 million in 2023, then gained by 28.05% to -$675.1 million in 2024, then slumped by 119.09% to -$1.5 billion in 2025, then surged by 72.2% to -$411.2 million in 2026.
• The last three Tax Provisions figures came in at -$411.2 million (Q1 2026), -$1.5 billion (Q4 2025), and -$421.0 million (Q3 2025), per Business Quant data.